

Q3 report 2018 Press and analyst presentation

25 October, 2018

Per Strömberg, CEO Sven Lindskog, CFO






Improved EBIT

Logistic costs weighing down profits

High activity level continues






Improved EBIT and high activity level

- Net sales in local currency +5%
- Underlying sales development +4.2%, driven by volume and price
- Stable EBIT margin

Events

- Apotek Hjärtat and Minutkliniken in joint venture with Min Doktor
- Launch of ICA Spara
- Dark store to move to permanent location this week

MSEK	Q3 2018	Q3 2017	Change %
Net sales	28,846	27,164	6.2
EBIT	1,499	1,380	8.6
EBIT Margin	5.2%	5.1%	0.1 pp



EBIT equals EBIT excluding items affecting comparability on all slides in this presentation.



ICA SWEDEN

ICA Store sales growth estimated to be above market

Store sales and market in Q3

ICA store sales growth of +3.4%, comparable stores +2.8%

• Sales mainly driven by increased number of store visitors


Price and calendar effect of +2.4% (price +2.7%, calendar -0.3%)

ICA Online sales growth +41% (food online +47%, menu baskets +6%).

 256 ICA stores selling food online and 605 stores offer menu baskets

Q3 establishments: 1 new store

Sales development for ICA stores in Sweden (incl. VAT)



The graph will be updated when final market data is available at the end of November



Market share trend is expected to improve


Store sales and market in Q3

Rimi store sales +2.9%, comparable sales +2.3%

- Estonia comparable -0.9%
- Latvia comparable +4.4%
- Lithuania comparable +1.0%

Establishments Q3: no new stores

Sales development for Rimi Baltic stores



The graph will be updated when final market data is available in November



APOTEK HJÄRTAT Sales development slightly above market growth

Store sales and market in Q3

Apotek Hjärtat sales growth +9.6%, adjusted growth +3.0% (constant prices prescription drugs), including negative calendar effect of -0.3%


- Prescription +10.3%
- OTC +1.2%
- Traded goods +12.2%

Market growth of +9.3%. Adjusted +2.2%

- Prescription +9.6%
- OTC +1.1%
- Traded goods +12.9%

Very strong online growth, Apotek Hjärtat +55%, market growth +37%

Sales development for Apotek Hjärtat pharmacies





Highlights



Online continues to grow rapidly



Online sales growth Q3 2018 vs Q3 2017



Dark store in permanent location will open this week

- Increased volumes in ICA's online business
 - Sales YTD 2018 ~1,200 MSEK, +45% growth
 - Home delivery share ~50%
 - Online share of sales in active stores ~3%
 - In total ~260 stores selling food online ("Lösplock")
- ~50 stores have signed up for our Dark store in Stockholm by end of September
 - >450 stores use our Dark store for menu baskets
- New warehouse in Jordbro, south of Stockholm, handles all menu baskets since September
- Handling of food online ("Lösplock") starts this week
- Number of orders handled every week have doubled since after the summer






Apotek Hjärtat and Minutkliniken in joint venture with Min Doktor

- Apotek Hjärtat invests in Min Doktor, a leading provider of digital primary care services, to offer customers accessible healthcare
- By combining Min Doktor's Swedish operations with Minutkliniken's drop-in clinics adjacent to several of Apotek Hjärtat's pharmacies, patients can get help both online and at clinics staffed by nurses
- Min Doktor is planning for a rapid expansion of the number of clinics, primarily located adjacent to ICA stores
- ICA Gruppen's investment in Min Doktor consists of a capital contribution of SEK 335 million plus ICA Gruppen's other contributions, including the Minutkliniken business, which is valued at SEK 225 million
- Apotek Hjärtat owns 42% of the joint venture
- The deal has been approved by the competition authorities and the transaction will close on November 1, 2018






ICA Spara together with new partnerships has been launched



New group strategy for plastics

- Several initiatives to successively reduce the environmental impact of the plastics used in the product range
- The strategy covers the design and shape of products and packages, smart use of material, and product and packaging innovations
- ICA Gruppen will e.g. stop selling disposable items made of plastics such as straws, glasses/mugs, plates, cutlery, cotton swabs, by 2020 and instead use reusable material
- The goal is to contribute to a circular and sustainable plastics system
- Read more in our Sustainability report for Q3 on www.icagruppen.se





Financials



Strong sales and recovering EBIT

Net sales +5% in local currency. Underlying growth including impact from high-price drugs, +4.2%

EBIT improving, partly from one-offs

Operating cash-flow fluctuations due to calendar effects

EPS affected by low tax last year

MSEK	Q3 2018	Q3 2017	Change %
Net Sales	28,846	27,164	6.2
EBIT ¹	1,499	1,380	8.6
EBIT margin %	5.2%	5.1%	0.1 pp
Cash flow ²	583	854	-31.7
Earnings per share (SEK)	5.36	5.45	-1.7

¹ EBIT Q3 2018 includes costs related to the previously planned integration of IKI of 0 MSEK (11) ² Cash flow from operating activities excl. ICA Bank





EBIT variance analysis Q3 (estimate)

	MSEK
EBIT Q3 2017	1,380
Sales Volume	165
Margin	85
Store costs	-105
Other costs	-37
Acquisition and integration related costs	11
EBIT Q3 2018	1,499





Recovery, but logistic costs still challenging

Net sales growth +4.3%

- Wholesale growth continuing
- Positive impact from higher buying percentage and price inflation

Higher EBIT

- + Sales volume
- + Higher store profit sharing
- + Gross margin before logistics costs
- Logistic costs
- Ramp-up of dark store
- Investing in digitalization and development projects

MSEK	Q3 2018	Q3 2017	Change %
Net sales	20,730	19,869	4.3
EBIT	1,040	1,004	3.5
EBIT Margin	5.0%	5.1%	-0.0 pp





Actions ICA Sweden

Items

- Recover time lag in adjusting for spring 2018 currency deterioration
- Take cost saving actions and implement digital transformation at ICA's in-house advertising center
- Store profit sharing improving vs 2017
- Ramp-up of operations in Dark store will over time generate volumes reaching critical mass, and eliminate start-up challenges experienced during Q2 2018
- Reduce Logistics & Distribution costs

 Administrative cost reductions will be made to enable investment in digitalization and business development

Current status

- Done as from June 2018 (unless further SEK deteriorations)
- Improving in Q3
- Restructuring in process
- Exceptional improvement in Q3
- Will gradually improve over coming quarters

- No negative efficiency variance in Q3 vs LY
- Still, cost inflation/indices projections indicate increasing costs going forward
- Long-term plan being prepared
- The plan for this will be finalized by end 2018



Stable EBIT development in spite of higher cost pressure

Net sales growth in local currency +3.0%

• Volume growth improving

EBIT in local currency in line with last year

- + Price and mix
- + Stores post-conversion in Estonia
- + Improved PL margin
- Salary inflation in logistic costs and store operating costs
- Price investments in Lithuania

MSEK	Q3 2018	Q3 2017	Change %
Net sales	3,827	3,413	12.1
EBIT ¹	175	161	9.3
EBIT Margin	4.6%	4.7%	-0.1 pp

¹ EBIT Q3 2018 includes costs related to the previously planned integration of IKI MSEK 0 (9)



APOTEK HJÄRTAT Another strong quarter

Sales growth +9.8%

- Adjusted sales growth (constant prices prescription drugs) +3.0%
- Good volume development in comparable pharmacies and online
- Positive price mix and higher average price on traded goods

Good EBIT progress

- + Sales volume
- + Price/mix (category) driving underlying gross margin improvement
- Continued investment in e-commerce, digitalization and pharmacies

Adjusted EBIT margin (fixed price Prescribed) 4.9%

MSEK	Q3 2018	Q3 2017	Change %
Net sales	3,414	3,108	9.8
EBIT	155	130	19.7
EBIT Margin	4.5%	4.2%	0.4 pp





ICA REAL ESTATE

Stable net sales development and higher investments

Net sales slightly higher

 Increased volume from acquisitions and other investments +16 MSEK


EBIT in line with last year

- + Increased income from joint ventures and investments
- Higher depreciations and administration costs

Good and stable development of wholly owned Swedish real estate properties

- Updated market valuation, SEK 14.3 billion. Book value SEK 10.1 billion
- Market value including joint ventures (50% ownership) SEK 19.8 billion. Book value SEK 14.5 billion.

MSEK	Q3 2018	Q3 2017	Change %
Net sales	648	609	6.5
whereof owned properties	255	233	9.2
Net Yield	6.7%	6.6%	0.1 pp
EBIT	122	121	0.6
EBIT Margin	18.7%	19.9%	-1.2 pp





CONTINUED PROGRESS IN NET INCOME AND EBIT

Net income growing

- Customer loans, mortgages and corporate loans
- ICA Insurance customer growth (now ~137,000)

MSEK	Q3 2018	Q3 2017	Change %
Net income	341	245	39.4
EBIT	76	29	163.1
Business Volume	45,833	38,049	20.5

EBIT improvement

- + Net interest, volume driven
- + Improved result in ICA Insurance
- + One-off effect approximately 30 MSEK due to new agreement on forward flow of credit portfolio





HEMTEX

Sales held back by warm weather, but EBIT level sustained

Lower sales

- Fewer customer visits in stores
- Good growth in online sales
- Closure of seven stores this year

EBIT in line with Q3 last year

- Sales volume
- + Currency effects
- + Cost reductions

MSEK	Q3 2018	Q3 2017	Change %
Net sales	237	252	-6.0
EBIT	5	6	-15.6
EBIT Margin	2.4%	2.4%	-0.0 pp






Cash-flow seasonally weaker

Operating cash flow lower than last year

- Calendar effects
- A few minor suppliers added to supply chain financing program







Results overall in line with long term financial targets


Targets	R12 (30 Sep 2018), %	Long-term targets, %
Grow faster than market ¹	Sweden Baltics	
	Pharmacy 😑	All markets
EBIT margin excl. non-recurring items ²	4.1	4.5
ROCE ³	10.3	10
Net debt/EBITDA⁴	1.1x	<2.0x
Dividend (% profit of the year 2017)	53	At least 50

¹Swedish and Baltics growth based on latest definitive market data Q2, 2018

² The changeover to IFRS 15 entails a new determination that ICA Gruppen acts as a principal and not as an agent in a few contracts, which has an effect on the EBIT margin

³ Excluding ICA Bank

⁴Interest-bearing liabilities excluding pensions and ICA Bank minus cash and cash equivalents in relation to EBITDA, operating income before depreciation and impairment





Outlook and Summary



Outlook



ICA Sweden

- Logistic costs remain a challenge
- General review of organization
- Administration cost reductions to enable investments in digitalization and business development
- 10 store openings 2018 with focus on large cities

Rimi Baltic

- Construction phase of new DC in Riga
- Cost inflation increasing
- One Brand Strategy in Latvia
- 7-8 store openings in 2018

Apotek Hjärtat (pharmacy)

- Investment in online and last mile continues
- Strong focus on CRM
- Expanding Minutkliniken in joint venture with Min Doktor
- 6 new pharmacies in 2018

ICA Real Estate

• Continue to develop urban places with ICA stores and Apotek Hjärtat as a hub

ICA Bank

- Bank transformation proceeding
 Develop new digital services
 - Focus on customer loans and corporate loans
- ICA Insurance growth focus continues

Hemtex

- Focus on improving sales trend
- Further roll-out of new store concept, in total 16 this year






Improved EBIT

Logistic costs weighing down profits

High activity level continues







2018-10-25



Disclaimer

This information is such that ICA Gruppen AB is obligated to make public pursuant to the EU Market Abuse Regulation and the Swedish Securities Market Act. The information was submitted for publication October 25, 2018 at 7.00 CET.

This report contains forward-looking statements that reflect the Board of Directors' and management's current views with respect to certain future events and potential financial performance. Although the Board of Directors and the management believe that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct. Accordingly, results could differ materially from those set out in the forward-looking statements as a result of, among other factors, (i) changes in economic, market and competitive conditions, (ii) success of business and operating initiatives, (iii) changes in the regulatory environment and other government actions, (iv) fluctuations in exchange rates and (v) business risk management.

This report does not imply that the Company has undertaken to revise these forward-looking statements, beyond what is required under the company's registration contract with Nasdaq Stockholm, if and when circumstances arise that will lead to changes compared to the date when these statements were provided.

